BioMarin Pharmaceutical Inc. (BMRN) 22.75 +0.07

Trade BMRN
NOW!
Last Trade:22.75Short Ratio:6.10
Last Trade Time:1:27pmDay Range:22.42 - 22.79
Ask:22.75Year Range:11.37 - 23.87
Bid:22.74One Year Target:23.96
Open:22.64Exchange:NasdaqNM
Volume:267974EBITDA:33.0M
Prev. Close:22.68Market Cap:2.301B
50 Day Moving:20.8572Div Yield:
200 day moving:18.5171PE:

BioMarin to Present at the Barclays Capital Global Healthcare Conference

Posted on 03/17/10 at 9:06am
BioMarin to Present at the Barclays Capital Global Healthcare Conference PR Newswire NOVATO, Calif., March 17
Click here to read the rest of the article

Stocks That Created New 52-Week Highs (BGCP, BIIB, BMRN, BJRI, BRCM)

Posted on 03/10/10 at 3:51pm
BGC Partners Inc (NASDAQ: BGCP) shares added 2.42% to create a new 52-week high of $5.92.Analysts at Keefe Bruyette initiated coverage of BGCP with a “market perform” rating. Read more about this company here.
Click here to read the rest of the article
Posted in

Top Takeover Targets In The Biotechnology Sector This Year (VRTX, AUXL, CELG, ITMN, GENZ)

Posted on 03/09/10 at 9:09pm
Analysts at Morningstar have compiled a list of top takeover targets in the biotechnology sector this year. Morningstar said that it weighed drug portfolio strength, fit with potential partners, profit-boosting power, and financial health in assessing the chances of a takeover.
Click here to read the rest of the article
Posted in

Uptrend Spotted in Shares of BioMarin Pharmaceutical (BMRN)

Posted on 03/09/10 at 6:15am
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ: BMRN) on March 02, 2010 at $20.93. In approximately 1 week, BioMarin Pharmaceutical has returned 6.3% as of today's recent price of $22.25.
Click here to read the rest of the article

BioMarin to Present at the Cowen and Company 30th Annual Health Care Conference

Posted on 03/02/10 at 10:03am
BioMarin to Present at the Cowen and Company 30th Annual Health Care Conference PR Newswire NOVATO, Calif., March 2
Click here to read the rest of the article

BioMarin Supports Observance of Rare Disease Day February 28

Posted on 02/25/10 at 5:50pm
BioMarin Supports Observance of Rare Disease Day February 28 International Coalition Aims to Increase Public Awareness, Supportive Legislation and Drug Development For Patients with Rare Diseases; California Assembly Endorses State Date of Observance PR Newswire
Click here to read the rest of the article

BioMarin Pharmaceutical Earnings (BMRN)

Posted on 02/23/10 at 8:07pm
BioMarin Pharmaceutical (NASDAQ: BMRN) released their quarterly earnings today after the closing bell. The Novato, California based company reported net income of $4.7 million or $0.05 per share compared to $24.5 million or $0.21 per share in the year ago period.
Click here to read the rest of the article
Posted in

BioMarin Announces Fourth Quarter and Full Year 2009 Financial Results

Posted on 02/23/10 at 5:06pm
BioMarin Announces Fourth Quarter and Full Year 2009 Financial Results Fourth Quarter Profitability Driven by Continued Growth of Naglazyme and Kuvan Conference Call and Webcast to Be Held Today at 5:00 p.m. ET PR Newswire
Click here to read the rest of the article

Rodman Reports Record 2009 Financial Results

Posted on 02/09/10 at 9:26am
NEW YORK--(BUSINESS WIRE)-- Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) today announced financial results for the full year and the fourth quarter, ended December 31, 2009.
Click here to read the rest of the article

Benzinga’s Top Downgrades (BMRN, AMB, DNB, ARG, HK)

Posted on 02/08/10 at 10:21am
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) declined 0.62% to $19.37 in the pre-market session after BioMarin Pharmaceutical was downgraded by Brean Murray to Hold from Buy. The 52-week trading range for BMRN is $9.93 - $21.50. BioMarin Pharmaceutical closed at $19.49 in the previous trading session.
Click here to read the rest of the article
Posted in